Myovant Sciences Stock Crashes On Poor Trial Data For Prostate Cancer Treatment
Myovant Sciences posted poor trial data for part of a Phase 3 study for a prostate cancer treatment that awaits key FDA action later this year, and MYOV stock plummeted out of a buy zone.